PAK5-Egr1-MMP2 signaling controls the migration and invasion in breast cancer cell

Tumor Biology

Volumn 34, Issue 5, 2013, Pages 2721-2729

  Wang, Xiao Xia ^a   Cheng, Qian ^a   Zhang, Shang Nuan ^a   Qian, He Ya ^a   Wu, Jin Xia ^a   Tian, Hui ^a   Pei, Dong Sheng ^a   Zheng, Jun Nian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Egr1; Migration; MMP2; p21 activated kinase 5 (PAK5)

Indexed keywords

EID: 84885425470     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0824-x     Document Type: Article

References (36)

1. Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem. 2001;34:347-52.
2. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409-18.
3. Sells MA, Knaus UG, Bagrodia S, Ambrose DM, Bokoch GM, Chernoff J. Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Curr Biol. 1997;7:202-10.
4. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, et al. Cell migration: integrating signals from front to back. Science. 2003;302:1704-9.
5. Sells MA, Boyd JT, Chernoff J. P21-activated kinase 1 (PAK1) regulates cell motility in mammalian fibroblasts. J Cell Biol. 1999;145:837-49.
6. Jaffer ZM, Chernoff J. P21-activated kinases: three more join the Pak. Int J Biochem Cell Biol. 2002;34:713-7.
7. Dutartre H, Davoust J, Gorvel JP, Chavrier P. Cytokinesis arrest and redistribution of actin-cytoskeleton regulatory components in cells expressing the Rho GTPase CDC42HS. J Cell Sci. 1996;109(Pt 2):367-77.
8. Li X, Minden A. Targeted disruption of the gene for the PAK5 kinase in mice. Mol Cell Biol. 2003;23:7134-42.
9. Gong W, An Z, Wang Y, Pan X, Fang W, Jiang B, et al. P21-activated kinase 5 is overexpressed during colorectal cancer progression and regulates colorectal carcinoma cell adhesion and migration. Int J Cancer. 2009;125:548-55.
10. Cotteret S, Jaffer ZM, Beeser A, Chernoff J. p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol. 2003;23:5526-39.
11. Hangen E, Blomgren K, Benit P, Kroemer G, Modjtahedi N. Life with or without AIF. Trends Biochem Sci. 2010;35:278-87.
12. Zhang H, Li Z, Viklund EK, Stromblad S. P21-activated kinase 4 interacts with integrin alpha v beta 5 and regulates alpha v beta 5-mediated cell migration. J Cell Biol. 2002;158:1287-97.
13. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol. 2002;193:287-92.
14. Zcharia E, Atzmon R, Nagler A, Shimoni A, Peretz T, Vlodavsky I. Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor. Anticancer Drugs. 2012;23:1022-31.
15. Timm T, Matenia D, Li XY, Griesshaber B, Mandelkow EM. Signaling from MARK to tau: regulation, cytoskeletal crosstalk, and pathological phosphorylation. Neurodegener Dis. 2006;3:207-17.
16. Callow MG, Clairvoyant F, Zhu S, Schryver B, Whyte DB, Bischoff JR, et al. Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem. 2002;277:550-8.
17. Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML, et al. AR and ER interaction with a p21-activated kinase (PAK6). Mol Endocrinol. 2002;16:85-99.
18. Yang F, Li X, Sharma M, Zarnegar M, Lim B, Sun Z. Androgen receptor specifically interacts with a novel p21-activated kinase, PAK6. J Biol Chem. 2001;276:15345-53.
19. Pandey A, Dan I, Kristiansen TZ, Watanabe NM, Voldby J, Kajikawa E, et al. Cloning and characterization of PAK5, a novel member of mammalian p21-activated kinase-II subfamily that is predominantly expressed in brain. Oncogene. 2002;21:3939-48.
20. Tsang CM, Yip YL, Lo KW, Deng W, To KF, Hau PM, et al. Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. Proc Natl Acad Sci U S A. 2012;109:E3473-82.
21. Ferraz C, Lorenz S, Wojtas B, Bornstein SR, Paschke R, Eszlinger M. Inverse correlation of miRNA and cell cycle-associated genes suggests influence of miRNA on benign thyroid nodule tumorigenesis. J Clin Endocrinol Metab. 2013;98:E8-16.
22. Zhuo W, Zhang L, Wang Y, Zhu B, Chen Z. Cyclin D1 G870A polymorphism is a risk factor for esophageal cancer among Asians. Cancer Invest. 2012;30:630-6.
23. Vizkeleti L, Ecsedi S, Rakosy Z, Orosz A, Lazar V, Emri G, et al. The role of CCND1 alterations during the progression of cutaneous malignant melanoma. Tumour Biol. 2012;33:2189-99.
24. Lee MH, Yang HY. Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev. 2003;22:435-49.
25. Wang X, Gong W, Qing H, Geng Y, Zhang Y, Peng L, et al. p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells. Tumour Biol. 2010;31:575-82.
26. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem. 2002;277:13430-7.
27. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Litwack G, Alnemri ES. Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc Natl Acad Sci U S A. 1996;93:14486-91.
28. Dan C, Nath N, Liberto M, Minden A. PAK5, a new brain-specific kinase, promotes neurite outgrowth in N1E-115 cells. Mol Cell Biol. 2002;22:567-77.
29. Matenia D, Griesshaber B, Li XY, Thiessen A, Johne C, Jiao J, et al. PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic actin. Mol Biol Cell. 2005;16:4410-22.
30. Rosenberg GA. Matrix metalloproteinases in brain injury. J Neurotrauma. 1995;12:833-42.
31. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J. 1994;7:2062-72.
32. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 1990;9:289-303.
33. Woessner Jr JF, Gunja-Smith Z. Role of metalloproteinases in human osteoarthritis. J Rheumatol Suppl. 1991;27:99-101.
34. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89:1260-70.
35. Komatsu K, Nakanishi Y, Nemoto N, Hori T, Sawada T, Kobayashi M. Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathol. 2004;21:105-12.
36. Wang M, Wang T, Liu S, Yoshida D, Teramoto A. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol. 2003;20:65-72.